NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Price Target & More

$18.47 -0.39 (-2.07 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$18.47
Today's Range$18.18 - $18.82
52-Week Range$5.47 - $23.50
Volume758,386 shs
Average Volume1.45 million shs
Market Capitalization$2.01 billion
P/E Ratio-17.26
Dividend YieldN/A
Beta1.98

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Debt-to-Equity RatioN/A
Current Ratio2.53%
Quick Ratio2.48%

Price-To-Earnings

Trailing P/E Ratio-17.26
Forward P/E Ratio-17.93
P/E GrowthN/A

Sales & Book Value

Annual Sales$128.37 million
Price / Sales14.78
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book5.29

Profitability

EPS (Most Recent Fiscal Year)($1.07)
Net Income$-91,240,000.00
Net Margins-70.66%
Return on Equity-30.68%
Return on Assets-18.40%

Miscellaneous

Employees215
Outstanding Shares102,710,000

How to Become a New Pot Stock Millionaire

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals (NASDAQ:SPPI) issued its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.04. The biotechnology company earned $28.57 million during the quarter, compared to analyst estimates of $33.18 million. Spectrum Pharmaceuticals had a negative net margin of 70.66% and a negative return on equity of 30.68%. Spectrum Pharmaceuticals's quarterly revenue was down 18.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

What price target have analysts set for SPPI?

4 Wall Street analysts have issued 1-year price targets for Spectrum Pharmaceuticals' stock. Their predictions range from $25.00 to $33.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $29.00 in the next year. View Analyst Ratings for Spectrum Pharmaceuticals.

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
  • Mr. Kurt A. Gustafson, Exec. VP, CFO & Principal Accounting Officer (Age 50)
  • Mr. Thomas J. Riga, Chief Operating Officer
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
  • Mr. Keith McGahan, Sr. VP & Chief Legal Officer

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

Press coverage about SPPI stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 45.42 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include SHROTRIYA RAJESH C MD (5.92%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $18.47.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $2.01 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Spectrum Pharmaceuticals in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 57.01%. The high price target for SPPI is $33.00 and the low price target for SPPI is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$24.60$21.6667
Price Target Upside: 57.01% upside31.82% upside29.20% upside16.42% upside

Spectrum Pharmaceuticals (NASDAQ:SPPI) Consensus Price Target History

Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2018HC WainwrightBoost Price TargetPositive -> Buy$33.00HighView Rating Details
12/18/2017B. RileyInitiated CoverageBuy -> Buy$26.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$32.00N/AView Rating Details
10/20/2017Jefferies GroupBoost Price TargetBuy$25.00N/AView Rating Details
4/1/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/15/2016Royal Bank of CanadaSet Price TargetBuy$11.00 -> $10.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings History and Estimates Chart

Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings Estimates

2018 EPS Consensus Estimate: ($1.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.35)($0.31)($0.33)
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.33)($0.33)($0.33)
Q4 20181($0.33)($0.33)($0.33)

Spectrum Pharmaceuticals (NASDAQ SPPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018Q4 2017($0.25)($0.29)$33.18 million$28.57 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.16)($0.22)$33.27 million$36.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.27)($0.26)$30.50 million$34.30 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.20)($0.18)$32.23 million$29.10 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.27)($0.2190)$31.13 million$35.24 millionViewListenView Earnings Details
11/14/2016Q3 2016($0.30)($0.22)$29.53 million$33.39 millionViewN/AView Earnings Details
8/9/2016Q216($0.29)($0.05)$30.88 million$33.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.14)$28.83 million$43.90 millionViewN/AView Earnings Details
3/9/2016Q415($0.18)($0.06)$33.87 million$50.30 millionViewN/AView Earnings Details
11/4/2015Q315($0.25)($0.28)$31.87 million$28.46 millionViewN/AView Earnings Details
8/6/2015Q215($0.22)($0.01)$34.48 million$44.98 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$48.00 million$38.60 millionViewN/AView Earnings Details
3/13/2015Q414($0.16)$0.09$48.50 million$51.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)$0.08$45.00 million$47.99 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)$0.09$41.50 million$46.90 millionViewListenView Earnings Details
5/8/2014Q114($0.22)$0.01$39.49 million$40.10 millionViewListenView Earnings Details
3/6/2014Q313($0.11)$0.05$41.96 million$41.50 millionViewListenView Earnings Details
11/12/2013Q3($0.07)($0.13)$38.70 million$42.44 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.12)($0.08)$33.41 million$33.23 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.06)$49.88 million$38.67 millionViewN/AView Earnings Details
2/21/2013Q4 2012$0.16$0.18ViewN/AView Earnings Details
11/7/2012Q312$0.29$0.42$68.56 million$69.00 millionViewN/AView Earnings Details
8/8/2012Q2 2012$0.31$0.34ViewN/AView Earnings Details
4/26/2012Q1 2012$0.28$0.35ViewN/AView Earnings Details
3/1/2012Q4 2011$0.28$0.13ViewN/AView Earnings Details
10/28/2011Q3 2011$0.09$0.29ViewN/AView Earnings Details
8/4/2011Q2 2011$0.13$0.13ViewN/AView Earnings Details
5/4/2011Q1 2011$0.01$0.33ViewN/AView Earnings Details
3/10/2011Q4 2010($0.04)$0.14ViewN/AView Earnings Details
11/4/2010Q3 2010($0.22)($0.07)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.15)($0.20)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.15)($0.78)ViewN/AView Earnings Details
4/5/2010Q4 2009($0.20)($0.19)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.20)($0.17)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.14)($0.28)ViewN/AView Earnings Details
5/18/2009Q1 2009($0.11)$0.02ViewN/AView Earnings Details
3/31/2009Q4 2008($0.17)($0.12)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.32)($0.28)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.34)$0.34ViewN/AView Earnings Details
5/13/2008Q1 2008($0.40)($0.28)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.38)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Spectrum Pharmaceuticals (NASDAQ:SPPI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$0.1512/18/201212/20/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.33%
Institutional Ownership Percentage: 77.32%
Insider Trading History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Rajesh C Md ShrotriyaDirectorSell90,000$19.00$1,710,000.00200,652View SEC Filing  
4/17/2018Joseph W TurgeonCEOSell11,565$19.00$219,735.00316,509View SEC Filing  
4/16/2018Rajesh C Md ShrotriyaDirectorSell30,000$18.72$561,600.00200,652View SEC Filing  
4/16/2018Thomas J RigaCOOSell3,900$18.60$72,540.00254,694View SEC Filing  
4/13/2018Rajesh C Md ShrotriyaDirectorSell30,000$19.93$597,900.00200,652View SEC Filing  
4/11/2018Rajesh C Md ShrotriyaDirectorSell30,000$20.30$609,000.00200,652View SEC Filing  
4/9/2018Rajesh C Md ShrotriyaDirectorSell12,300$15.01$184,623.00200,652View SEC Filing  
4/6/2018Rajesh C Md ShrotriyaDirectorSell3,686$15.00$55,290.00200,652View SEC Filing  
4/4/2018Rajesh C Md ShrotriyaDirectorSell30,000$15.01$450,300.00200,652View SEC Filing  
4/2/2018Rajesh C Md ShrotriyaDirectorSell60,000$15.90$954,000.00200,652View SEC Filing  
4/2/2018Thomas J RigaCOOSell1,948$15.58$30,349.84256,452View SEC Filing  
3/28/2018Joseph W TurgeonCEOSell4,810$16.40$78,884.00328,074View SEC Filing  
3/28/2018Kurt A GustafsonCFOSell4,350$16.35$71,122.50187,193View SEC Filing  
3/28/2018Rajesh C Md ShrotriyaDirectorSell90,000$16.88$1,519,200.00200,652View SEC Filing  
3/26/2018Kurt A GustafsonCFOSell1,300$17.38$22,594.00191,543View SEC Filing  
3/26/2018Rajesh C Md ShrotriyaDirectorSell30,000$17.34$520,200.00200,652View SEC Filing  
3/26/2018Thomas J RigaCOOSell220$17.41$3,830.20251,476View SEC Filing  
3/22/2018Joseph W TurgeonCEOSell3,100$18.17$56,327.00332,884View SEC Filing  
3/22/2018Kurt A GustafsonCFOSell2,640$18.13$47,863.20192,843View SEC Filing  
3/21/2018Stuart Mitchell KrassnerDirectorSell4,200$18.64$78,288.0083,257View SEC Filing  
2/5/2013Anthony E Maida IIIDirectorSell5,000$12.25$61,250.00View SEC Filing  
11/12/2012Joseph Kenneth KellerCOOBuy10,000$10.95$109,500.00View SEC Filing  
11/1/2012Anthony E Maida IIIDirectorSell5,000$11.09$55,450.00View SEC Filing  
9/4/2012Anthony E Maida IIIDirectorSell5,000$12.01$60,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spectrum Pharmaceuticals (NASDAQ SPPI) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Spectrum Pharmaceuticals (SPPI) Will Announce Quarterly Sales of $26.10 MillionZacks: Analysts Anticipate Spectrum Pharmaceuticals (SPPI) Will Announce Quarterly Sales of $26.10 Million
www.americanbankingnews.com - April 20 at 1:06 AM
Spectrum Pharma (SPPI) Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other CancersSpectrum Pharma (SPPI) Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers
www.streetinsider.com - April 19 at 8:13 AM
 Brokerages Anticipate Spectrum Pharmaceuticals (SPPI) to Post -$0.24 EPS Brokerages Anticipate Spectrum Pharmaceuticals (SPPI) to Post -$0.24 EPS
www.americanbankingnews.com - April 18 at 11:22 PM
Spectrum Pharmaceuticals (SPPI) CEO Sells $219,735.00 in StockSpectrum Pharmaceuticals (SPPI) CEO Sells $219,735.00 in Stock
www.americanbankingnews.com - April 18 at 7:46 PM
Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 30,000 SharesSpectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 30,000 Shares
www.americanbankingnews.com - April 18 at 7:29 PM
Rajesh C. Md Shrotriya Sells 90,000 Shares of Spectrum Pharmaceuticals (SPPI) StockRajesh C. Md Shrotriya Sells 90,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 18 at 7:16 PM
Spectrum Pharmaceuticals: What To Expect From This Powerful GrowerSpectrum Pharmaceuticals: What To Expect From This Powerful Grower
seekingalpha.com - April 18 at 8:15 AM
Thomas J. Riga Sells 3,900 Shares of Spectrum Pharmaceuticals (SPPI) StockThomas J. Riga Sells 3,900 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 17 at 7:28 PM
Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American ...Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American ...
www.businesswire.com - April 17 at 5:56 PM
Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in ChicagoSpectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago
finance.yahoo.com - April 17 at 5:56 PM
Spectrum Pharmaceuticals (SPPI) Lowered to "Sell" at Zacks Investment ResearchSpectrum Pharmaceuticals (SPPI) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 16 at 1:19 PM
Spectrum Pharmaceuticals (SPPI) Lowered to "Buy" at BidaskClubSpectrum Pharmaceuticals (SPPI) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 14 at 9:13 PM
Spectrum Pharmaceuticals (SPPI) Director Sells $597,900.00 in StockSpectrum Pharmaceuticals (SPPI) Director Sells $597,900.00 in Stock
www.americanbankingnews.com - April 13 at 7:13 PM
Rajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals (SPPI) StockRajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 13 at 7:13 PM
Wait for a Pullback Before Rolling the Dice on SPPI StockWait for a Pullback Before Rolling the Dice on SPPI Stock
investorplace.com - April 12 at 9:25 PM
Form 4 SPECTRUM PHARMACEUTICALS For: Apr 06 Filed by: SHROTRIYA RAJESH C MDForm 4 SPECTRUM PHARMACEUTICALS For: Apr 06 Filed by: SHROTRIYA RAJESH C MD
www.streetinsider.com - April 12 at 8:33 AM
Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock OptionsImplied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options
finance.yahoo.com - April 12 at 8:33 AM
Spectrum Pharmaceuticals (SPPI) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowSpectrum Pharmaceuticals (SPPI) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 12 at 8:33 AM
Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC PatientsWired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients
finance.yahoo.com - April 12 at 8:33 AM
Spectrum Pharmaceuticals (SPPI) Upgraded at Zacks Investment ResearchSpectrum Pharmaceuticals (SPPI) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:45 PM
Spectrum Down Following Positive Cancer Drug TestSpectrum Down Following Positive Cancer Drug Test
www.baystreet.ca - April 11 at 5:34 PM
7 Stocks To Watch For April 11, 20187 Stocks To Watch For April 11, 2018
www.benzinga.com - April 11 at 8:28 AM
BioSci Rounds Report: Strong Data Catapulted Spectrum While Intercept Is Poised For GrowthBioSci Rounds Report: Strong Data Catapulted Spectrum While Intercept Is Poised For Growth
seekingalpha.com - April 11 at 8:28 AM
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On DataYour Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data
seekingalpha.com - April 11 at 8:28 AM
Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes CareToday’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes Care
finance.yahoo.com - April 11 at 8:28 AM
Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 12,300 Shares of StockInsider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 12,300 Shares of Stock
www.americanbankingnews.com - April 10 at 10:16 PM
Rajesh C. Md Shrotriya Sells 3,686 Shares of Spectrum Pharmaceuticals (SPPI) StockRajesh C. Md Shrotriya Sells 3,686 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 10 at 10:16 PM
Spectrum Pharmaceuticals (SPPI) Is Up Sharply On Study ResultsSpectrum Pharmaceuticals (SPPI) Is Up Sharply On Study Results
www.nasdaq.com - April 10 at 5:31 PM
Spectrum Pharmaceuticals (SPPI) Shares Cross Above 200 DMASpectrum Pharmaceuticals (SPPI) Shares Cross Above 200 DMA
www.nasdaq.com - April 10 at 5:31 PM
Why Spectrum Pharmaceuticals, Inc. Is Soaring TodayWhy Spectrum Pharmaceuticals, Inc. Is Soaring Today
finance.yahoo.com - April 10 at 5:31 PM
Why Sprint, Spectrum Pharmaceuticals, and NVIDIA Jumped TodayWhy Sprint, Spectrum Pharmaceuticals, and NVIDIA Jumped Today
finance.yahoo.com - April 10 at 5:31 PM
Spectrum Pharmaceuticals (SPPI) PT Raised to $13.00 at Jefferies GroupSpectrum Pharmaceuticals (SPPI) PT Raised to $13.00 at Jefferies Group
www.americanbankingnews.com - April 8 at 8:05 PM
Spectrum Pharmaceuticals (SPPI) Lowered to Sell at BidaskClubSpectrum Pharmaceuticals (SPPI) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 4 at 9:30 AM
Spectrum Pharmaceuticals Target of Unusually Large Options Trading (SPPI)Spectrum Pharmaceuticals Target of Unusually Large Options Trading (SPPI)
www.americanbankingnews.com - April 4 at 6:52 AM
CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences ConferenceCASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference
www.bizjournals.com - April 3 at 8:19 AM
Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10thSpectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th
finance.yahoo.com - April 3 at 8:19 AM
Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and InsmedToday’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed
finance.yahoo.com - April 3 at 8:19 AM
Spectrum Pharmaceuticals (SPPI) Expected to Post Quarterly Sales of $26.10 MillionSpectrum Pharmaceuticals (SPPI) Expected to Post Quarterly Sales of $26.10 Million
www.americanbankingnews.com - April 3 at 2:08 AM
ValuEngine Upgrades Spectrum Pharmaceuticals (SPPI) to "Buy"ValuEngine Upgrades Spectrum Pharmaceuticals (SPPI) to "Buy"
www.americanbankingnews.com - April 3 at 12:00 AM
Thomas J. Riga Sells 1,948 Shares of Spectrum Pharmaceuticals (SPPI) StockThomas J. Riga Sells 1,948 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - April 2 at 10:41 PM
Spectrum Pharmaceuticals (SPPI) Director Sells $954,000.00 in StockSpectrum Pharmaceuticals (SPPI) Director Sells $954,000.00 in Stock
www.americanbankingnews.com - April 2 at 10:21 PM
 Analysts Expect Spectrum Pharmaceuticals (SPPI) Will Announce Earnings of -$0.31 Per Share Analysts Expect Spectrum Pharmaceuticals (SPPI) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - April 1 at 11:26 PM
Spectrum Pharmaceuticals (SPPI) Receives Consensus Rating of "Buy" from AnalystsSpectrum Pharmaceuticals (SPPI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 1 at 5:28 PM
Kurt A. Gustafson Sells 4,350 Shares of Spectrum Pharmaceuticals (SPPI) StockKurt A. Gustafson Sells 4,350 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - March 28 at 10:46 PM
Spectrum Pharmaceuticals (SPPI) CEO Sells $78,884.00 in StockSpectrum Pharmaceuticals (SPPI) CEO Sells $78,884.00 in Stock
www.americanbankingnews.com - March 28 at 10:46 PM
Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 30,000 Shares of StockInsider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 30,000 Shares of Stock
www.americanbankingnews.com - March 28 at 10:32 PM
Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 90,000 SharesSpectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 90,000 Shares
www.americanbankingnews.com - March 28 at 10:31 PM
Kurt A. Gustafson Sells 1,300 Shares of Spectrum Pharmaceuticals (SPPI) StockKurt A. Gustafson Sells 1,300 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - March 27 at 11:14 PM
Spectrum Pharmaceuticals (SPPI) Stock Rating Lowered by TheStreetSpectrum Pharmaceuticals (SPPI) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - March 24 at 12:28 AM
Spectrum Pharmaceuticals (SPPI) Director Sells $78,288.00 in StockSpectrum Pharmaceuticals (SPPI) Director Sells $78,288.00 in Stock
www.americanbankingnews.com - March 23 at 7:32 PM

SEC Filings

Spectrum Pharmaceuticals (NASDAQ:SPPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spectrum Pharmaceuticals (NASDAQ:SPPI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spectrum Pharmaceuticals (NASDAQ SPPI) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.